AstraZeneca Presents the Updated Results of Imfinzi (durvalumab) in P-III CASPIAN Trial for the Treatment of Extensive-Stage Small Cell Lung Cancer at ESMO 2021
Shots:
- The P-III CASPIAN trial evaluates Imfinzi + CT or Imfinzi + CT + tremelimumab vs CT alone in 805 patients with ES-SCLC in 200+ centers across 23 countries- including the US- EU- South America- Asia & Middle East
- The results showed OS benefits & sustained efficacy after a median follow-up of ≥3yrs. with a 29% reduction in risk of death; m-OS (12.9 vs 10.5mos.)- well-tolerated safety profile consistent with the known profiles of the therapy- patients experienced a serious AEs (32.5% vs 36.5%)
- In an exploratory analysis- patients were alive @3yrs. (17.6% vs 5.8%) & survival benefits were consistent across all subgroups. The therapy is also being evaluated in the P-III ADRIATIC trial for SCLC
| Ref: Businesswire | Image: New Europe
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com